Overview: Flow Cytometry CD34 Stem Cell Panel
Introduction: The Flow Cytometry CD34 Stem Cell Panel is a diagnostic tool designed to enumerate stem cells using whole blood samples. In India, CD34+ cell count is critical for hematopoietic stem cell transplantation (HSCT) mobilization and graft assessment (~10,000â€"15,000 transplants/year for thalassemia, leukemia), as well as stem cell disorders. High morbidity from under-monitoring in rural/low-SES transplant patients, limited flow labs, delayed mobilization or graft failure leading to engraftment delay or rejection. Per hematology practices aligned with ICMR and Indian Society of Blood and Marrow Transplantation guidelines, the test employs flow cytometry for CD34+ cell count, total stem cells, and viability over 1-2 days with high accuracy, valuable for peripheral blood stem cell collection and post-transplant evaluation. This diagnostic falls under transplant evaluation and targets HSCT candidates/donors, addressing accurate detection to guide apheresis timing and graft quality. With elevated morbidity due to under-testing, the test supports public health efforts by enabling precise stem cell quantification and improving transplant success. Its whole blood-based approach ensures reliable enumeration.
Other Names: Flow CD34 Pnl.
FDA Status: FDA approved, CLIA certified for hematology, compliant with 2025 standards.
Historical Milestone: CD34 flow standard for HSCT; in India, used in transplant centers.
Purpose: The test assesses 3 parameters including CD34+ cell count to guide stem cell enumeration, assess graft quality, inform transplant.
Test Parameters: 1. CD34+ Cell Count, 2. Total Stem Cells, 3. Viability.
Pretest Condition: No fasting required; patients should be HSCT candidates/donors.
Specimen: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for flow).
Medical History: Patients should provide details on mobilization, transplant type, donor status.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of poor graft quality including failure, benefits of enumeration, and minimal discomfort from blood draw.
Procedural Considerations: The test involves sample processing using flow cytometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low cell count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Adequate CD34+ count indicates good graft; low may require remobilization, necessitating specialist input.
Specialist Consultation: Transplant hematologists should be consulted for management.
Additional Supporting Tests: CFU-GM, viability dyes for confirmation.
Test Limitations: Requires viable cells; comprehensive approach required.
References: Indian Journal of Hematology 2024, Transplant Studies India 2023.
